kinesin family member 2AGenealiases: CDCBM3 · HK2 · KIF2
Q-omics provides the consensus-scored KIF2A profile across patient tissues and cancer cell-line models. KIF2A expression is associated with patient survival in 31 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KIF2A is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, KIF2A protein abundance shows 25,536 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRP, and GBM as cancer lineages where KIF2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF2A survival associations across molecular data types. KIF2A RNA expression shows survival associations in the most cancer types (31), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF2A RNA expression–survival associations across cancer types. High KIF2A expression shows unfavorable associations in MESO, LIHC, ACC and KICH, but favorable associations in COAD and READ. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for KIF2A RNA expression.
This table summarizes KIF2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIF2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF2A shows higher tumor expression in KIRP, LIHC, LUAD, KIRC, BRCA and COAD. The KIRP box plot shows higher KIF2A RNA expression in tumor versus normal tissue (log2 FC = +0.884, t-test p = .003).
This table shows molecular features associated with KIF2A in patient tissues and cancer cell lines. In patient samples, KIF2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
